CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 PORTERS FIVE FORCES ANALYSIS
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry
3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS
3.5.1 Drivers
3.5.1.1 Increasing incidence of chronic and infectious diseases
3.5.1.2 Technological advancements in IVD
3.5.1.3 Emergence of minimal invasive technologies
3.5.1.4 Increasing government expenditures on healthcare
3.5.1.5 Increase in popularity of personalized medicine approach
3.5.2 Restraint
3.5.2.1 Unclear reimbursement policies
3.5.2.2 Stringent regulatory policies
3.5.3 Opportunity
3.5.3.1 Potential opportunities for outsourcing
3.5.3.2 Convergence of new technologies
CHAPTER 4 IVD MARKET, BY PRODUCT TYPE
4.1 OVERVIEW
4.1.1 Market size and forecast
4.2 REAGENTS
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 INSTRUMENTS
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 SOFTWARE AND SERVICES
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 IVD MARKET, BY TECHNIQUE
5.1 OVERVIEW
5.1.1 Market size and forecast
5.2 IMMUNODIAGNOSTICS
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 Enzyme-linked immunosorbent assay (ELISA)
5.2.4.1 Market size and forecast
5.2.4.2 Chemiluminescence immunoassay (CLIA)
5.2.4.2.1 Market size and forecast
5.2.4.3 Fluorescence immunoassay (FIA)
5.2.4.3.1 Market size and forecast
5.2.4.4 Colorimetric immunoassay (CI)
5.2.4.4.1 Market size and forecast
5.2.5 Rapid tests
5.2.5.1 Market size and forecast
5.2.6 Enzyme-linked immunospot (ELISPOT)
5.2.6.1 Market size and forecast
5.2.7 Radioimmunoassay (RIA)
5.2.7.1 Market size and forecast
5.2.8 Western blot
5.2.8.1 Market size and forecast
5.3 BLOOD TESTING
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.4 MOLECULAR DIAGNOSTICS
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Polymerize chain reaction (PCR)
5.4.4.1 Market size and forecast
5.4.5 Isothermal nucleic acid technology (INAAT)
5.4.5.1 Market size and forecast
5.4.6 Hybridization
5.4.6.1 Market size and forecast
5.4.7 DNA diagnostics
5.4.7.1 Market size and forecast
5.4.8 Microarray
5.4.8.1 Market size and forecast
5.4.9 Others
5.4.9.1 Market size and forecast
5.5 TISSUE DIAGNOSTICS
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.6 CLINICAL CHEMISTRY
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.6.4 Basic metabolic panel
5.6.4.1 Market size and forecast
5.6.5 Liver panel
5.6.5.1 Market size and forecast
5.6.6 Renal profile
5.6.6.1 Market size and forecast
5.6.7 Lipid profile
5.6.7.1 Market size and forecast
5.6.8 Thyroid function panel
5.6.8.1 Market size and forecast
5.6.9 Electrolyte panel
5.6.9.1 Market size and forecast
5.6.10 Speciality chemicals
5.6.10.1 Market size and forecast
5.7 OTHER IVD TECHNIQUES
5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast
CHAPTER 6 IVD MARKET, BY APPLICATION
6.1 INFECTIOUS DISEASES
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.2 CANCER
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.3 CARDIAC DISEASES
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.4 IMMUNE SYSTEM DISORDERS
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.5 NEPHROLOGICAL DISEASES
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.6 GASTROINTESTINAL DISEASES
6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast
6.7 OTHERS INDICATIONS
6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast
CHAPTER 7 IVD MARKET BY END USERS
7.1 STANDALONE LABORATORIES
7.1.1 Market size and forecast
7.2 HOSPITALS
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 ACADEMIC AND MEDICAL SCHOOLS
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 POINT OF CARE TESTING
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.5 OTHERS END-USER
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
CHAPTER 8 ASIA-PACIFIC IVD MARKET
8.1 Key market trends
8.2 Key growth factors and opportunities
8.3 Market size and forecast
8.4 India
8.4.1 Market size and forecast
8.5 China
8.5.1 Market size and forecast
8.6 Japan
8.4.6.1 Market size and forecast
8.7 Australia
8.7.1 Market size and forecast
8.8 South Korea
8.8.1 Market size and forecast
8.9 Rest of Asia-Pacific
8.9.1 Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 THERMO FISHER SCIENTIFIC INC.
9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and development
9.2 ALERE INC.
9.2.1 Company overview
9.2.2 Business performance
9.2.3 Key strategies and developments
9.3 BIOMERIEUX
9.3.1 Company overview
9.3.2 Business performance
9.3.3 Key strategies and developments
9.4 DANAHER CORPORATION
9.4.1 Company overview
9.4.2 Business performance
9.4.3 Key strategies and development
9.5 F. HOFFMANN-LA ROCHE AG
9.5.1 Company overview
9.5.2 Business performance
9.5.3 Key strategies and developments
9.6 BECTON DICKINSON AND COMPANY
9.6.1 Company overview
9.6.2 Business performance
9.6.3 Key strategies and development
9.7 BIO-RAD LABORATORIES
9.7.1 Company overview
9.7.2 Business performance
9.7.3 Key strategies and developments
9.8 BAYER AG
9.8.1 Company overview
9.8.2 Business performance
9.8.3 Key strategies and development
9.9 SYSMEX CORPORATION
9.9.1 Company overview
9.9.2 Business performance
9.9.3 Key strategies and developments
9.10 JOHNSON & JOHNSON
9.10.1 Company overview
9.10.2 Business performance
9.10.3 Key strategies and development
